普乐沙福目前的临床适应症。
Current clinical indications for plerixafor.
作者信息
Fruehauf Stefan
机构信息
Department of Hematology/Oncology, Paracelsus Klinik, Osnabrück, Germany.
出版信息
Transfus Med Hemother. 2013 Aug;40(4):246-50. doi: 10.1159/000354229. Epub 2013 Jul 19.
Abstract
Autologous and allogeneic hematopoietic stem cell (HSC) transplantation are considered the standard of care for many malignancies including lymphoma, multiple myeloma, and some leukemias. In many cases, mobilized peripheral blood has become the preferred source for HSCs. Plerixafor, an inhibitor of the interaction between CX chemokine receptor 4 (CXCR4) and stromal derived factor-1 alpha (SDF-1), has been evaluated in clinical trials and approved by the FDA and EMA. This agent has very modest toxicity and appears to be quite potent at HSC mobilization. Current clinical indications for the use of plerixafor are the subject of this review.
摘要
自体和异基因造血干细胞（HSC）移植被认为是许多恶性肿瘤（包括淋巴瘤、多发性骨髓瘤和某些白血病）的标准治疗方法。在许多情况下，动员的外周血已成为HSC的首选来源。普乐沙福是一种CX趋化因子受体4（CXCR4）与基质衍生因子-1α（SDF-1）相互作用的抑制剂，已在临床试验中进行评估，并获得了美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）的批准。该药物毒性非常轻微，在HSC动员方面似乎相当有效。本文综述了普乐沙福目前的临床应用指征。
相似文献
1
Current clinical indications for plerixafor.
Transfus Med Hemother. 2013 Aug;40(4):246-50. doi: 10.1159/000354229. Epub 2013 Jul 19.
2
Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Clin Ther. 2010 May;32(5):821-43. doi: 10.1016/j.clinthera.2010.05.007.
3
Plerixafor: a peripheral blood stem cell mobilizer.
Pharmacotherapy. 2010 May;30(5):485-92. doi: 10.1592/phco.30.5.485.
4
Physiology and pharmacology of plerixafor.
Transfus Med Hemother. 2013 Aug;40(4):237-45. doi: 10.1159/000354132. Epub 2013 Jul 19.
5
Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.
Drugs Today (Barc). 2009 Jul;45(7):497-505. doi: 10.1358/dot.2009.45.7.1395292.
6
Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Biol Blood Marrow Transplant. 2010 May;16(5):695-700. doi: 10.1016/j.bbmt.2009.12.538. Epub 2010 Jan 11.
7
[Research Progress on the Application Strategies of Plerixafor in the Peripheral Blood Stem Cell Mobilization for Autologous Transplantation--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Feb;32(1):322-326. doi: 10.19746/j.cnki.issn.1009-2137.2024.01.053.
8
Novel strategies for blood stem cell mobilization: special focus on plerixafor.
Expert Opin Biol Ther. 2011 Sep;11(9):1241-8. doi: 10.1517/14712598.2011.601737.
9
Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Eur J Haematol. 2011 Apr;86(4):299-304. doi: 10.1111/j.1600-0609.2010.01573.x. Epub 2011 Jan 31.
10
[Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
Med Clin (Barc). 2016 Sep 2;147(5):223.e1-223.e7. doi: 10.1016/j.medcli.2016.05.019. Epub 2016 Jun 30.
引用本文的文献
1
Outcomes of upfront plerixafor use for mobilization in germ cell tumor patients.
Hematol Transfus Cell Ther. 2024 Nov;46 Suppl 5(Suppl 5):S37-S42. doi: 10.1016/j.htct.2023.12.008. Epub 2024 Mar 4.
2
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.
Biomolecules. 2022 Jun 4;12(6):784. doi: 10.3390/biom12060784.
3
Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update.
J Blood Med. 2021 Jun 2;12:403-412. doi: 10.2147/JBM.S307520. eCollection 2021.
4
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Int J Mol Sci. 2021 Jan 11;22(2):659. doi: 10.3390/ijms22020659.
5
CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.
Int J Nanomedicine. 2019 Apr 26;14:2927-2944. doi: 10.2147/IJN.S171280. eCollection 2019.
6
Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.
Transfus Med Hemother. 2018 Jan;45(1):24-31. doi: 10.1159/000478911. Epub 2017 Oct 4.
7
CXCR4 blockade decreases CD4+ T cell exhaustion and improves survival in a murine model of polymicrobial sepsis.
PLoS One. 2017 Dec 12;12(12):e0188882. doi: 10.1371/journal.pone.0188882. eCollection 2017.
8
Consider the chemokines: a review of the interplay between chemokines and T cell subset function.
Discov Med. 2017 Aug;24(130):31-39.
9
The pathogenic role of angiogenesis in rheumatoid arthritis.
Angiogenesis. 2015 Oct;18(4):433-48. doi: 10.1007/s10456-015-9477-2. Epub 2015 Jul 22.
10
Protecting the Health and Safety of Cell and Tissue Donors.
ISBT Sci Ser. 2015 Apr 1;10(Suppl 1):108-114. doi: 10.1111/voxs.12150.
本文引用的文献
1
Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
Biol Blood Marrow Transplant. 2017 Aug;23(8):1282-1289. doi: 10.1016/j.bbmt.2017.04.024. Epub 2017 May 2.
2
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
J Clin Apher. 2013 Oct;28(5):359-67. doi: 10.1002/jca.21280. Epub 2013 Jun 14.
3
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Am J Hematol. 2013 Sep;88(9):754-7. doi: 10.1002/ajh.23499. Epub 2013 Jul 23.
4
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Leuk Lymphoma. 2014 Feb;55(2):331-6. doi: 10.3109/10428194.2013.802783. Epub 2013 Jun 14.
5
Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Bone Marrow Transplant. 2013 Oct;48(10):1279-84. doi: 10.1038/bmt.2013.52. Epub 2013 Apr 15.
6
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
Biol Blood Marrow Transplant. 2013 Jan;19(1):87-93. doi: 10.1016/j.bbmt.2012.08.010. Epub 2012 Aug 23.
7
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
Transfusion. 2013 Jan;53(1):76-84. doi: 10.1111/j.1537-2995.2012.03719.x. Epub 2012 May 25.
8
Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.
Ann Hematol. 2012 Jul;91(7):1073-9. doi: 10.1007/s00277-012-1411-8.
9
Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice.
Blood. 2012 Jan 19;119(3):707-16. doi: 10.1182/blood-2011-04-348904. Epub 2011 Nov 2.
10
Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
Mol Ther. 2012 Jan;20(1):230-8. doi: 10.1038/mt.2011.195. Epub 2011 Sep 27.
Zotero 插件